To investigate the impact of picrasidine J on cellular signaling pathways, we determined the expression of MAPK pathway components (ERK, P38, and JNK) and AKT in HNSCC cells treated with picrasidine J. As observed in Figure 6A–C, the picrasidine J treatment significantly reduced the phosphorylation of ERK in both cell lines. Here, AKT1 is linked to head and neck squamous cell carcinoma.